Urology
Volume 72, Issue 6 , Pages 1198-1202 , December 2008

Is Quantitative Histologic Examination Useful to Predict Nonorgan-Confined Prostate Cancer When Saturation Biopsy Is Performed?

  • P. Pepe

      Affiliations

    • Department of Urology, Cannizzaro Hospital, Catania, Italy
    • Corresponding Author InformationRequest reprints: Pietro Pepe, M.D., Divisione di Urologia, Ospedale Cannizzaro, Via Messina 829, Catania 95126 Italy
    • ,
  • F. Fraggetta

      Affiliations

    • Department of Pathology, Cannizzaro Hospital, Catania, Italy
    • ,
  • A. Galia

      Affiliations

    • Department of Urology, Cannizzaro Hospital, Catania, Italy
    • ,
  • G. Grasso

      Affiliations

    • Department of Pathology, Cannizzaro Hospital, Catania, Italy
    • ,
  • S. Piccolo

      Affiliations

    • Department of Economy and Territory, University of Catania, Catania, Italy
    • ,
  • F. Aragona

      Affiliations

    • Department of Urology, Cannizzaro Hospital, Catania, Italy

Received 1 September 2007 ,Accepted 15 May 2008.

References 

  1. Partin AW, Kattan MW, Subong EN, et al. Combination of PSA, clinical stage and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA. 1997;277:1445–1451
  2. Walsh PC, DeWeese TL, Eisenberger MA. Localized prostate cancer. N Engl J Med. 2007;357:2696–2705
  3. Kattan MW, Stapleton AM, Wheeler TM, et al. Evaluation of a nomogram used to predict pathologic stage of clinically localized prostate carcinoma. Cancer. 1997;79:528–537
  4. Algaba F, Arce Y, Oliver A, et al. Prognostic parameters other than Gleason score for the daily evaluation of prostate cancer in needle biopsy. Eur Urol. 2005;48:566–571
  5. Poulos CK, Daggy JK, Cheng L. Prostate needle biopsies: Multiple variables are predictive of final tumor volume in radical prostatectomy. Cancer. 2004;101:527–532
  6. D'Amico AV, Renshaw AA, Cote K, et al. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favourable intermediate-risk disease. J Clin Oncol. 2004;22:3726–3732
  7. Freedland SJ, Aronson WJ, Csathy GS, et al. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: Results from the search database. Urology. 2003;61:742–747
  8. Grossklaus DJ, Coffey CS, Shappell SB, et al. Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. J Urol. 2002;167:2032–2035
  9. Naya Y, Slaton JW, Troncoso P, et al. Tumor length and location of cancer on biopsy predict for side specific extraprostatic cancer extension. J Urol. 2004;171:1093–1097
  10. Gancarczyk KJ, Wu H, McLeod DG, et al. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: The center for prostate disease research nomograms. Urology. 2003;61:589–595
  11. Suekane S, Noguchi M, Nakashima O, et al. Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy. Int J Urol. 2007;14:713–718
  12. Pepe P, Galia A, Fraggetta F, et al. Prediction by quantitative histology of pathological stage in prostate cancer. Eur J Surg Oncol. 2005;31:309–313
  13. Walz J, Graefen M, Chun FK, et al. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol. 2006;50:498–505
  14. Sajadi KP, Kim T, Terris MK, et al. High yield of saturation prostate biopsy for patients with previous negative biopsies and small prostates. Urology. 2007;70:691–695
  15. Pepe P, Aragona F. Saturation prostate needle biopsy and prostate cancer at initial and repeat evaluation. Urology. 2007;70:1131–1135
  16. Aragona F, Pepe P, Motta M, et al. Incidence of prostate cancer in Sicily: Results of a multicenter case-findings protocol. Eur Urol. 2005;47:569–574
  17. Bostwick DG, Grignon DJ, Hammond ME, et al. Prognostic factors in prostate cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:995–1000
  18. Veltri RW, Miller MC, Partin AW, et al. Prediction of prostate carcinoma stage by quantitative biopsy pathology. Cancer. 2001;91:2322–2328
  19. Felix K, Chun H, Karakiewicz PI, et al. Prostate cancer nomograms: An update. Eur Urol. 2006;50:914–926
  20. Freedland SJ, Terris MK, Csathy GS, et al. Search Database Study Group Preoperative model for predicting PSA recurrence after radical prostatectomy using percent of biopsy with cancer, biopsy Gleason grade and serum PSA. J Urol. 2004;171:2215–2220
  21. Nelson CP, Rubin MA, Strawderman M, et al. Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy. Urology. 2002;59:740–745
  22. Freedland SJ, Csathy GS, Dorey F, et al. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than PSA or Gleason score. J Urol. 2002;167:516–520
  23. Nelson CP, Dunn RL, Wei JT, et al. Contemporary preoperative parameters predict cancer-free after radical prostatectomy: A tool to facilitate treatment decisions. Urol Oncol. 2003;21:213–218
  24. Gao X, Mohideen N, Flanigan RC, et al. The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: Implications for treatment selection. J Urol. 2000;164:1982–1986
  25. Bismar TA, Lewis JS, Vollmer RT, et al. Multiple measures of carcinoma extent versus perineural invasion in prostate needle biopsy tissue in prediction of pathologic stage in a screening population. Am J Surg Pathol. 2003;27:432–440
  26. Joniau S, Hsu CY, Lerut E, et al. A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. Eur Urol. 2007;51:388–394
  27. Haese A, Chaudhari M, Miller MC, et al. Quantitative biopsy pathology for the prediction of pathologically organ-confined prostate cancer: A multiinstitutional validation study. Cancer. 2003;97:969–978
  28. Epstein JL, Walsh PC, Carmichael M. Pathological and clinical findings to predict tumor extent of non palpable (stage T1c) prostate cancer. JAMA. 1994;271:368–374

PII: S0090-4295(08)00752-8

doi: 10.1016/j.urology.2008.05.045

Urology
Volume 72, Issue 6 , Pages 1198-1202 , December 2008

Article Tools

* Image Usage & Resolution